传统与新型口服抗真菌药治疗皮肤癣菌性趾甲甲真菌病的相对影响:网络Meta分析
本研究采用贝叶斯网络Meta分析,比较口服抗真菌药单药治疗成人皮肤癣菌性趾甲甲真菌病的相对疗效。共纳入21项研究、35种方案,发现药物剂量与疗效相关,特比萘芬250mg每日24周的1年真菌学治愈 odds 显著高于250mg每日12周(OR 2.62,95%可信区间1.57-4.54),部分三唑类药物可能比特比萘芬更有效。
要点
- 特比萘芬250mg每日24周的1年真菌学治愈 odds 显著高于250mg每日12周(OR 2.62,95%CI 1.57-4.54)。
- 药物剂量与疗效相关,增强方案可提高疗效。
- 部分三唑类药物可能比特比萘芬更有效。
核心结论
- 这是首个针对皮肤癣菌性趾甲甲真菌病单药抗真菌药及其不同剂量的网络Meta分析。
- 研究结果可为选择最合适的抗真菌药物提供指导,尤其在特比萘芬耐药问题日益受关注的情况下。
研究设计与样本
- 贝叶斯网络Meta分析,检索PubMed、Scopus、EMBASE(Ovid)和CINAHL,纳入21项研究,评估成人皮肤癣菌性趾甲甲真菌病口服抗真菌药单药治疗的疗效。
- 共识别35种方案,其中新型药物包括泊沙康唑和奥特康唑。
主要发现
- 特比萘芬250mg每日24周的1年真菌学治愈 odds 显著高于250mg每日12周(OR 2.62,95%可信区间1.57-4.54),SUCRA分别为92.4%和66.3%。
- 药物剂量与疗效相关,增强方案可提高疗效。
- 部分三唑类药物可能比特比萘芬更有效。
关键数值与推荐
- 疗效终点:1年真菌学治愈和1年完全治愈。
- 安全性终点:1年任何不良事件计数、1年因任何不良事件停药 odds、1年因肝脏问题停药 odds。
- 比较了新型方案与传统方案如特比萘芬250mg每日12周和伊曲康唑200mg每日12周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a paucity of evidence regarding the relative therapeutic efficacy of treatments for onychomycosis. OBJECTIVES: We determined the relative efficacy of monotherapies for dermatophyte toenail onychomycosis with Bayesian network meta-analyses (NMAs). METHODS: We searched PubMed, Scopus, EMBASE (Ovid) and CINAHL to identify studies that investigated the efficacy of monotherapy with oral antifungals for dermatophyte toenail onychomycosis in adults. In this paper, 'regimen' corresponds to a given agent and its dosage. The relative effects and surface under the cumulative ranking curve (SUCRA) values of the various regimens were estimated; evidence quality was assessed at the study level and across networks. RESULTS: Data from 21 studies were used. Our two efficacy-related endpoints were: (i) mycological and (ii) complete cure at 1 year; safety--related endpoints were: (i) 1-year count of any adverse event (AE), (ii) 1-year odds of discontinuation due to any AE, (iii) 1-year odds of discontinuation due to liver issues. Thirty-five regimens were identified; the newer agents among these included posaconazole and oteseconazole. We compared the efficacy of newer regimens with traditional ones like 'terbinafine 250 mg daily for 12 weeks' and 'itraconazole 200 mg daily for 12 weeks. We found that an agent's dosage was associated with its efficacy; for example, the 1-year odds of mycological cure with terbinafine 250 mg daily for 24 weeks (SUCRA = 92.4%) were significantly greater than those of terbinafine 250 mg daily for 12 weeks (SUCRA = 66.3%) (odds ratio 2.62, 95% credible interval 1.57-4.54). We also found that booster regimens can increase efficacy. Our results showed that some triazoles could be more effective than terbinafine. CONCLUSIONS: This is the first NMA study of monotherapeutic antifungals - and their various dosages - for dermatophyte toenail onychomycosis. Our findings could provide guidance for the selection of the most appropriate antifungal agent, especially amid the growing concerns about terbinafine resistance.
引用
- Gupta AK, Venkataraman M, Bamimore MA, et al. Relative impact of traditional vs. newer oral antifungals for dermatophyte toenail onychomycosis: a network meta-analysis study. Br J Dermatol. 2023. PMID: 37253047. doi:10.1093/bjd/ljad070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。